Objective Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk. We aimed to determine detailed metabolic effects of genetically-induced ANGPTL3 deficiency in fasting and postprandial state.
HIGHLIGHTS
• ANGPTL3 deficiency results in similar reductions in LDL cholesterol and many triglyceride-rich lipoprotein lipids measures, such as VLDL cholesterol, with no evidence of substantial adverse effects on the comprehensive panel of circulating metabolite biomarkers tested here. • In particular, ANGPTL3 deficiency results in reduction of cholesterol content in triglyceride-rich lipoproteins and their remnants, which have been highlighted as risk factor for cardiovascular disease independently of LDL levels. • Homozygous ANGPTL3 loss-of-function carriers show essentially no postprandial increase in triglyceride-rich lipoproteins and fatty acids in response to a fat challenge, and display consistently elevated postprandial levels of ketone bodies and lactate when compared to noncarriers, suggesting enhanced hepatic fatty acid beta-oxidation.
INTRODUCTION
Considerable risk for cardiovascular disease (CVD) persists in individuals treated with lowdensity lipoprotein (LDL) cholesterol lowering statin and PCSK9 inhibitor therapies 1 . Experimental models and human genetics have indicated that triglyceride-rich lipoproteins (TRL) play a causal role in the pathogenesis of CVD 2 . Post-hoc analyses of statin trials have further shown that reductions of TRL is associated with lower cardiovascular event risk independently of the LDL cholesterol reduction achieved from statins 3, 4 . These observations have accelerated the development of novel TRL-lowering therapeutics for CVD prevention, with drug targets informed by recent discoveries from genetic studies 5 . These include identification of loss-of-function (LOF) mutations in the angiopoietin-like 3 gene (ANGPTL3) causing familial combined hypolipidemia (FHBL2; OMIM #605019) 6, 7 . This Mendelian condition is characterized by simultaneous presentation of low circulating concentrations of triglycerides, LDL cholesterol and high-density lipoprotein (HDL) cholesterol levels, as well as potential beneficial effects on glucose metabolism 7 .
ANGPTL3 is a protein secreted by the liver, and its deficiency was first identified in a hypolipidemic mouse strain 8 . The ANGPTL3 protein is as a potent inhibitor of lipoprotein lipase, a primary factor that clears TRL from the circulation 9 . Reduced ANGPTL3 also reduce hepatic apolipoprotein (apo) B secretion and increased hepatic LDL uptake, leading to reduced plasma LDL cholesterol levels 10 . ANGPTL3 further acts to inhibit endothelial lipase, which may contribute to the low HDL cholesterol levels in ANGPTL3 LOF carriers 11 . The first human ANGPTL3 LOF mutations described were nonsense mutations S17X and E129X in the first exon of the gene 6 . Since the initial publications on these mutations, several other ANGPTL3 LOF mutations have been characterized [12] [13] [14] . Individuals with complete ANGPTL3 deficiency have been reported to lack significant coronary atherosclerotic plaques 15 . Exome sequencing of large epidemiological cohorts have further shown that heterozygous carriers of ANGPTL3 LOF variants have a 35-40% reduced risk of coronary artery disease compared to the general population 15, 16 . Moreover, no increased prevalence in fatty liver disease, or other apparent adverse health effects have been identified for ANGPTL3 LOF carriers, including homozygote carriers with complete ANGPTL3 deficiency 7, 17 . Thus, ANGPTL3 is a promising therapeutic target for lowering CVD risk, and clinical trials of monoclonal antibodies or antisense oligonucleotides for ANGPTL3 inhibition have recently shown to lead to substantial lowering of circulating triglycerides and LDL cholesterol levels. 16, 18 Despite the promising results from phase 1 trials targeting ANGPTL3 16, 18 , a number of important questions of the molecular effects of ANGPTL3 inhibition remain. First, it is unclear which specific lipid components of TRL are mostly affected by ANGPTL3 deficiency, and thus the underlying mechanism of reduced CVD risk is incomplete understood. Second, the effects of ANGPTL3 deficiency on many emerging biomarkers for cardiometabolic risk have not been addressed 9 . We have previously shown that nuclear magnetic resonance (NMR) metabolomics is a powerful method to characterize the fine-grained effects of PCSK9 and HMGCR genetic variants on a lipid metabolism and other metabolic pathways, with a close match to the changes observed in statin trials 19, 20 . Here, we use NMR metabolomics to characterize the systemic effects of ANGPTL3 deficiency on detailed measures of lipoprotein composition, fatty acids, and circulating metabolites. Because most people are in a non-fasting state for the majority of the day, studying the effects on postprandial metabolism may further contribute to explain the cardioprotective mechanism of ANGPTL3 deficiency. We have previously reported highly reduced postprandial response in triglycerides among ANGPTL3 LOF homozygotes 21 . Here we further examined the detailed metabolic effects of ANGPTL3 deficiency after a high fat meal.
MATERIAL AND METHODS

Study cohort of ANGPTL3 loss-of-function carriers
An overview of the study design in shown in the "Graphic summary". The study population and the design of the oral fat tolerance challenge have been described in detail elsewhere 21 . Briefly, 6 homozygous and 32 heterozygous carriers of ANGPTL3 S17X LOF mutation (henceforth ANGPTL3 LOF) and 38 non-carriers were considered in the present study. Clinical examinations and blood sample drawings were performed after an overnight fast, after which participants underwent an oral fat tolerance test. The test meal (muffin prepared with olive oil, eggs, ricotta cheese, nuts, cocoa, wheat flour, and skimmed milk) consisted of 73 g fat, 52 g carbohydrate, 22 g protein, and 145 mg cholesterol. Blood samples were drawn before the test meal and at 2, 4, and 6 hours after the meal. The Ethical Committee of Sapienza University of Rome approved the study protocol and all study participants provided their informed consent.
Lipid and metabolite quantification
Frozen EDTA plasma samples from fasting state and those collected during the oral fat tolerance test were used for metabolomic analyses. Metabolic biomarkers were quantified using proton NMR metabolomics (Nightingale Health Ltd, Helsinki, Finland). This method provides simultaneous quantification of routine lipids, lipoprotein subclass profiling with lipid concentrations within 14 subclasses, fatty acid composition, and various low-molecular metabolites including amino acids, ketone bodies and gluconeogenesis-related metabolites in molar concentration units. Details of the experimentation and applications of the NMR metabolomics platform have been described previously 19, 20, 22, 23 .
Statistical analysis
We first evaluated associations between ANGPTL3 LOF carrier status and fasting metabolite measures. Prior to analyses, the concentrations of all metabolic markers were log-transformed and scaled to standard deviation (SD) units to enable comparison of results for measures with different units and across wide ranges of concentrations. As the primary analysis, we examined an additive model for association between metabolites and the three genotype classes (ANGPTL3 LOF homozygotes, heterozygotes, and noncarriers). For each metabolic measure, the concentration difference (in log-transformed and subsequently SD-scaled units) per ANGPTL3 LOF allele was calculated using linear regression adjusted for age and gender. As a secondary analysis, we studied the associations of complete ANGPTL3 knockouts and fasting metabolites using a recessive model (homozygous carriers vs. heterozygotes and noncarriers combined). Due to the correlated nature of metabolomics measures, significance level was defined to be 0.05/23, where 23 is the number of principal components explaining 99% of the variation of all metabolic measures at fasting state.
To evaluate postprandial responses in metabolites, we calculated means and standard errors by ANGPTL3 LOF carrier status at each time point. Postprandial dynamics in the three genotype classes were compared using net incremental area under the curve (iAUC) statistics (AUC that differs from the fasting value) with the trapezoidal rule 24 . The differences in iAUCs between the three genotype classes were tested with t-tests.
RESULTS
Study participants
The clinical characteristics of the study participants are summarized in Table 1 . ANGPTL3 LOF carriers and noncarriers were comparable for age, gender, body mass index, and waist-hipratio. Plasma levels of ANGPTL3 protein were undetectable in homozygotes, while heterozygotes had 51% lower concentration compared to that of noncarriers. The three genotype classes were comparable for dietary intake, physical activity, smoking prevalence and use of anti-inflammatory medications 21 . Descriptive statistics for all metabolic biomarkers tested are reported in Supplementary Table 1 .
Effects of ANGPTL3 loss-of-function on lipids and metabolites at fasting
Compared with noncarriers, carriers of ANGPTL3 LOF mutations had substantially reduced levels in almost all lipid measures assayed by NMR metabolomics. These include lower concentrations of routine lipid measures, as well as the cholesterol and triglyceride levels in major subfractions and reduced concentrations of apolipoproteins B and A1 (Figure 1 , Supplementary Table 2 ). Scaled to the same variation in each lipid measure (i.e. in units of SD), we observed comparable extent of lowering effects on LDL cholesterol levels (-0.74 SD-units of concentration per allele, [95% confidence interval -1.06 to -0.42]) as observed for VLDL cholesterol levels (-0.75, 95% CI -1.05 to -0.45) and other measures of TRL. The lowering effect size on total plasma triglycerides was -0.62 (95% CI -0.93 to -0.32). In absolute concentrations, these lowering effects correspond to 0.28 mmol/L lower for LDL cholesterol, 0.13 mmol/L lower for VLDL cholesterol, and 0.20 mmol/L for total triglycerides. Also HDL cholesterol and other lipid measures in HDL particles were lowered to a similar extend when scaled to SD-concentrations of same variation. The effects of ANGPTL3 LOF on all tested metabolites are shown in Supplementary Figures 1-2 .
Zooming in on the more specific effects of ANGPTL3 LOF on lipoprotein subclass measures, we observed substantial reduction of cholesterol concentration within all lipoprotein subclasses (Figure 2A) . The lowering effects were somewhat stronger for intermediate-density lipoprotein (IDL) in comparison to other apoB-100 containing particles. For HDL subclasses, cholesterol levels were most prominently lowered in medium-sized HDL particles. Scaled to the same variation, the extent of cholesterol lowering in all 10 apoB-containing subclasses was broadly similar to that observed for the routine lipid measures. Analogously, the triglyceride concentration in all lipoprotein subclasses (except for small HDL) were reduced; however the triglyceride lowering was to a somewhat smaller extent for IDL and other similarly-sized lipoprotein particles than that observed for cholesterol. Thus, even though the absolute triglyceride levels in lipoprotein particles were reduced, the relative proportion of triglycerides in TRL particles was actually increased due to ANGPTL3 deficiency. Concordantly, the cholesterol proportion of medium-sized and small VLDL and IDL particles decreased (Figure 2A lower panels). This is further illustrated in Figure 2B , which depicts the overall lipid composition for selected lipoprotein subclasses in ANGPTL3 LOF carriers and noncarriers. For example, the proportion of cholesterol in small VLDL was 36% in noncarriers, 34% in ANGPTL3 LOF heterozygotes and 26% in homozygotes. The cholesterol proportion was also reduced in large LDL (67%, 66%, and 62%, respectively), whereas in large HDL, ANGPTL3 LOF homozygotes had the highest proportion of cholesterol (55% vs. 47% and 46% in ANGPTL3 LOF heterozygotes and noncarriers, respectively).
The substantial lowering effects of ANGPTL3 deficiency on lipoprotein lipids may influence both absolute concentrations of circulating fatty acid and their relative proportions. We found that ANGPTL3 LOF carriers displayed a significant reduction of total fatty acids, including saturated, monounsaturated, and polyunsaturated omega-3 and omega-6 fatty acids (Figure 3) . Assessment of the proportions of fatty acid classes (i.e. their ratios relative to total fatty acids) indicated an elevation of the proportion of saturated fatty acids and a reduction in the proportion of omega-3 fatty acids.
To assess potential nonlipid effects of ANGPTL3 deficiency, we examined the changes in circulating amino acids, glycolysis and gluconeogenesis substrates and products, ketone bodies, and other metabolites quantified simultaneously alongside lipid measures by the NMR metabolomics platform. Several of these nonlipid biomarkers also showed significant association with ANGPTL3 LOF carrier status (Figure 3) . The ketone body betahydroxybutyrate, a biomarker of hepatic fatty acid beta-oxidation, was markedly elevated in ANGPTL3 LOF carriers (0.55 SD per allele, 95% CI 0.21 to 0.89). Further, the energy metabolism intermediate acetate was reduced (-0.56 SD per allele, 95% CI -0.90 to -0.22). Citrate levels also displayed a similar tendency. Branched-chained and aromatic amino acids, which are biomarkers for increased type 2 diabetes and CVD risk 23, 25 , did not differ between ANGPTL LOF carriers and noncarriers. Further, we observed no robust differences in creatinine, an indicator of kidney function, or in glycoprotein acetyls (GlycA) level, a marker of chronic inflammation.
In analyses employing a recessive model there was evidence for individuals with complete ANGPTL3 deficiency having more than twice the lipid lowering effects of heterozygote Table 3 ). None of the non-lipid markers were significant in the recessive model or displayed evidence for deviation from an additive model ( Supplementary Figures 3-4 , Supplementary Table 3 ).
Effects of ANGPTL3 loss-of-function on metabolic response to a fat challenge
To examine the effects of ANGPTL3 deficiency on postprandial metabolism, we further assessed the lipoprotein and metabolite trajectories after an oral fat challenge. Postprandial responses in selected metabolic measures for ANGPTL3 LOF carriers and noncarriers are shown in Figure 4 . ANGPTL3 LOF homozygotes had drastically lower concentration of cholesterol in VLDL, LDL and IDL particles in all timepoints in comparison to ANGPTL3 LOF heterozygotes and noncarriers. There was essentially no change in VLDL cholesterol after the fat challenge among ANGPTL3 LOF homozygotes, whereas ANGPTL3 LOF heterozygotes and noncarriers showed substantially increased levels (PiAUC = 0.07 for difference in iAUC). This effect on VLDL cholesterol seemed to be driven particularly by differences for large and medium sized VLDL particles in response to the high fat meal. For instance, both ANGPTL3 LOF heterozygotes and non-carriers displayed more than 80% increase in cholesterol in large VLDL at four hours after the meal when compared to ANGPTL3 LOF homozygotes (PiAUC=0.02 for ANGPTL3 LOF homozygotes versus noncarriers). In contrast, the high fat meal did not give rise to an increase in cholesterol levels of small VLDL, IDL and LDL particles for any of the groups; rather, there was a small decrease in cholesterol within these smaller apoB-carrying lipoprotein particles.
The postprandial response to the oral fat challenge in total fatty acids, beta-hydroxybutyrate and lactate are shown in Figure 4 . Homozygous ANGPTL3 LOF carriers had markedly lower total fatty acids at all time points in comparison to the other two groups, and showed essentially no postprandial increase in fatty acid concentrations. While the absolute concentration of omega-3 fatty acids was essentially unaffected by the fat challenge, the proportion of omega-3 fatty acids to total fatty acids increased after the meal in ANGPTL3 LOF homozygotes compared to other groups (PiAUC=0.0003, Supplementary Figure 5 ). The responses in absolute levels of saturated and monounsaturated fatty acids followed similar patterns as that of total fatty acids, with essentially no postprandial response for ANGPTL3 LOF homozygotes; however, the relative proportion of monounsaturated fatty acids increased for all groups (Supplementary Figure 5) . The shape of the postprandial response in ketone bodies was broadly similar for ANGPTL3 LOF carriers and noncarriers, but the concentrations of beta-hydroxybutyrate were maintained elevated in the homozygous ANGPTL3 LOF carriers (Figure 4) . ANGPTL3 LOF carriers also displayed consistently higher lactate levels after the fat meal challenge, and increases in postprandial citrate and acetate levels. Among other non-lipid biomarkers, glycoprotein acetyl (GlycA; a marker of chronic inflammation) levels showed a blunted postprandial response in ANGPTL3 LOF carriers, possibly indicating a smaller inflammatory effect of the high fat meal (PiAUC=0.03, Figure 4 ). Postprandial responses for other selected biomarkers are shown in Supplementary Figure 6 .
DISCUSSION
In the present work we describe a detailed metabolic signature associated with ANGPTL3 deficiency in humans. Because ANGPTL3 deficiency is known to influence postprandial lipid metabolism via modulation of lipoprotein lipase activity 21 , we considered it particularly interesting to investigate the fine-grained metabolic effects of ANGPTL3 LOF also after a highfat meal. We found that ANGPTL3 deficiency is characterized by markedly low levels of fasting and postprandial LDL and VLDL cholesterol, as well as other measures of TRL. In particular, individuals with two inactivating mutations in ANGPTL3 and no measurable concentration of ANGPTL3 protein showed essentially no increase in TRL in response to a high fat meal. The very low lipid levels among these homozygote carriers, who effectively act as human knockouts for ANGPTL3, were maintained after the oral fat challenge without evidence for adverse compensatory effects on the extensive metabolic biomarker panel examined in this study.
The main findings of our study are 4-fold: First, we found that ANGPTL3 deficiency results in similar reductions in magnitude for LDL and VLDL cholesterol, when scaled to the same variation in each lipid measure. Thus, ANGPTL3 inhibitors should be more effective in lowering VLDL cholesterol as compared to statins or PCSK9 inhibitors 19, 20 , suggesting added benefit of ANGPTL3 inactivating therapy in individuals with combined dyslipidemias. This finding has clinical relevance, because increasing evidence suggest that the cholesterol content of VLDL and other TRL are causally implicated in the development of CVD, independent of LDL cholesterol 2,3,26 . Although TRL have been suggested to play a causal role in CVD in Mendelian randomization studies 27 , the triglycerides per se are unlikely to be the causal factor because these lipids are not accumulating in the atherosclerotic plaque. In contrast, the cholesterol within TRL and their remnants can accumulate in the arterial intima, and even get trapped more easily than LDL cholesterol 2 . In line with our results, a recent phase 1 trial on antisense oligonucleotides targeting hepatic ANGPTL3 messenger RNA has reported up to 60% reduction in VLDL cholesterol and 33% reduction in LDL cholesterol 18 .
Second, the detailed profiling of lipoprotein subclasses revealed that the absolute concentrations of both cholesterol and triglycerides in most lipoprotein subclasses were reduced in ANGPTL3 LOF carries compared to noncarriers. However, the proportion of cholesterol (relative to the total lipid concentration in a given subclass) was reduced and the proportion of triglycerides increased in small and medium-sized VLDL and IDL subclasses. These results indicate that ANGPTL3 deficiency leads to less cholesterol load in the composition of TRL, which could potentially contribute to explain the lower CVD risk observed among ANGPTL3 LOF carriers. We observed no clear differences in the patterns of postprandial response of TRL measures for ANGPTL3 LOF heterozygotes as compared to noncarriers. In contrast, there was a remarkable lack of increase in TRL after the fatty meal intake among the 6 individuals with complete ANGPTL3 deficiency, as observed previously with more narrow measures of lipid metabolism 21, 28 . This lack of a dose-dependent postprandial response could suggest that therapeutic inhibition of ANGPTL3 may not alleviate the increase in TRL after a meal intake unless protein levels of ANGPTL3 are lowered to a very high extent. To this regard, we have recently determined that plasma ANGPTL3 less than 60 ng/ml represents a critical threshold associated with marked reductions in fasting lipid and lipoprotein concentrations 29 . Initial trial results have demonstrated therapeutic reductions of plasma ANGPTL3 concentration of up to 85% 18 . Further studies are required to elucidate whether this extent of ANGPTL3 protein depletion is sufficient to substantially blunt the postprandial response in TRL or whether complete ANGPTL3 deficiency is required to observe this.
Third, we found that ANGPTL3 deficiency causes an elevation of fasting concentrations of the ketone beta-hydroxybutyrate, which was maintained throughout the postprandial response. During ketogenesis in the liver, fatty acids are converted into ketone bodies via beta-oxidation to produce energy. As ketogenesis is elevated when the influx of fatty acids into the liver is increased 30 , the present observation may indicate that complete ANGPTL3 deficiency is accompanied by an increased hepatic utilization of fatty acids derived from the lipolysis of TRL or from adipose tissue. However, since the shape of postprandial response in betahydroxybutyrate and the other ketone body measured, acetoacetate, was similar independent of the ANGPTL3 carrier status, one could speculate that this phenomenon might be related to partitioning of adipose tissue-derived fatty acid during the interprandial phase. However, this issue requires further investigations. Similarly to beta-hydroxybutyrate, lactate levels were consistently higher at fasting and after the meal challenge for complete ANGPTL3 deficiency. This may indicate an enhanced conversion of pyruvate to lactate instead of its routing to the acetate pathway, consistent with the reduced concentration of acetate in the LOF carriers. These observations may suggest that ANGPTL3 deficiency is causing a modest shift of energy substrate utilization. The potential health effects of enhanced ketone body production remain unclear, but large epidemiological studies have generally reported only weak or null associations of ketone bodies with cardiometabolic risk factors and disease outcomes 22 .
A further insight from this study arises from the metabolic biomarkers not associated with ANGPTL3 deficiency, in particular for the homozygous carriers. These null results suggest there are no substantial adverse effects of complete absence of ANGPTL3 protein on amino acids and glycolysis-related metabolites, neither at fasting nor as a compensatory mechanism for the absence of postprandial lipid increase. This is informative for the safety of ANGPTL3 inhibiting therapeutics, because many of these metabolites have been shown to be biomarkers of the risk for type 2 diabetes and CVD events 23, 25 . This is also the case for several of the relative proportions of fatty acid analyzed in this study. The observed modulations in the fatty acid balance for the relative proportions of saturated and omega-3 fatty acids could potentially be unfavorable in terms of cardiovascular risk, but the causal relations of these measures remain unclear. For the postprandial effects, it is noteworthy that the inflammatory biomarker glycoprotein acetyls was low in ANGPTL3 LOF homozygotes, and less elevated in the postprandial stage; such blunted increase in low-grade inflammation in response to a fatty meal might contribute to additional risk-reducing effects beyond lipids. Overall, these results illustrate the potential of wider metabolic profiling of human knockouts for drug targets for elucidating molecular mechanisms and potential metabolic side effects.
The strengths of the present study include a unique setting with fasting and postprandial measurements in ANGPTL3 LOF carriers, including the rare instance of six individuals with complete ANGPTL3 deficiency. We used NMR metabolomics to obtain detailed measures of lipid metabolism and non-lipid biomarkers from multiple metabolic pathways. However, we acknowledge that other metabolomics assays capable of capturing additional blood metabolites could further contribute to characterize the metabolic effects beyond lipid metabolism. Despite the large effects on many lipid levels caused by ANGPTL3 deficiency, the small sample size provided limited power to detect all relevant metabolic associations, in particular for robustly comparing differences in the postprandial response. Our study was limited to characterize carriers of ANGPTL3 S17X LOF mutation only. Thus, there is a need for further metabolic characterization of other LOF variants in the ANGPTL3 gene. Detailed metabolic profiling in large biobanks with sequencing information available provides an opportunity to enable this and further extend applications to other lipid-lowering targets 20, 31 .
In conclusion, this detailed metabolic profiling study demonstrates that ANGPTL3 deficiency is characterized by substantial reductions in VLDL particles and their remnants, and a lower cholesterol content in these lipoproteins. Further, complete ANGPTL3 deficiency leads to virtual absence of postprandial increase in TRL. These findings support the increasing body of evidence indicating that genetic inhibition of ANGPTL3 causes a broad range of beneficial lipid changes, without adverse compensatory metabolic effects. Detailed metabolic profiling in trials of pharmacologic inactivation of ANGPTL3 could further help to confirm these findings in clinical settings and, in combination with the genetic evidence, uncover potential off-target effects 32 . 
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